

WEDNESDAY

16 September

08:00 - 09:30 SESSION 7

Reproductive biomarkers

Chairs: Associate professor *Kirstine Kirkegaard* (Horsens DK) and Associate professor *Else Marie Vestergaard* (Horsens DK)

08:00 - 08:30

State of the ART in Reproductive Biomarkers

Professor *Andres Salumets*

Department of Clinical Science, Intervention and Technology Karolinska Institutet, Stockholm, Sweden

08:30 - 09:00

FSHR variants and their significance in hormonal stimulation prior to IVF

Professor *Yvonne Lundberg Giwercman*

Clinical Research Center, Lund University, Lund, Sweden

09:00 - 09:30

Transcriptomic profiling in relation to complications of pregnancy

Professor *Thomas Hviid*

Department of Clinical Biochemistry, Zealand University Hospital, Køge Roskilde, Denmark

08:00 - 09:30 SESSION 8

Presentation of working groups (session by NSMB)

Chairs: Chief Physician *Morten Lindberg* (Tønsberg, NO) and Head of Medical Section *Erik Koldberg Amundsen* (Oslo, NO)

08:00 - 08:10

Introduction

Chief Physician *Morten Lindberg*

Department of Clinical Science, Intervention and Technology Karolinska Institutet, Stockholm, Sweden

08:10 - 08:30

Recommended use of HbA1c in patients with thalassemia or hemoglobin variant

Chief Physician *Eva Camilla Langsjøen*

Først Medical Laboratory, Oslo, Norway

08:30 - 08:50

TBA

08:50 - 09:30

Discussion about possible cooperation between the Nordic countries

08:00 - 09:30 SESSION 9

Extracellular vesicles as new diagnostic tools

Chair: Professor *Aase Handberg* (Aalborg, DK)

08:00 - 08:30

Potential of extracellular vesicles (EVs) as new disease markers. Experience from new EV based diagnostic tools for screening for ovarian cancer and pregnancy complications

Professor *Carlos Salomon*

UQ Centre for Extracellular Vesicle Nanomedicine, UQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia

08:30 - 08:50

Next Generation Diagnostics, a pipeline for extracellular vesicles based diagnostics of obesity complications and colon cancer

Associate Professor *Maiken Møllgaard* and Associate Professor *Malene Møller Jørgensen*

Department of Clinical Biochemistry and Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark

08:50 - 09:10

What needs to be addressed before extracellular vesicles could be used as diagnostic tools in routine clinical laboratories?

Research fellow *Kristiina Kurg*, MD PhD Institute of Clinical Medicine, Department of Internal Medicine, University of Tartu, Estonia

09:10 - 09:30

Discussion

09:45 - 10:30 PLENARY LECTURE

Sex, sex differences and biomarkers

Chair: Associate professor *Anne Winther Larsen* (Aarhus, DK)

Professor *Claus H. Gravholt*, Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark



How do we determine sex? In a clinical setting we determine sex based on chromosomal sex (46,XY or 46,XX), gonadal sex (testis or ovaries), hormonal sex (testosterone or estrogen), and anatomical sex (internal (to have a uterus or not) and external (penis or vagina)). This is usually straightforward in most cases, however in case of disorders of sex development (DSD) there may be incongruity between these different levels of sex and for example we may see an individual with a typical feminine appearance and 46,XY, testis, high levels of testosterone and without a uterus (46,XY female DSD with androgen insensitivity). Patients with DSD typically presents a challenge, when assessing biochemical measures, and this may initially lead to confusion, until a diagnosis is reached. In addition to these levels of sex, which are easily determined clinically, we also talk about the social gender or the perception of oneself, which again may not be congruent with the sex assigned at birth. Some of these individuals choose to change sex – transpersons. In transpersons (female-to-male (FtM), male-to-female (MtF)), many biochemical measures will change in line with the administered sex steroid therapy.

10:45 -12:00 PLENARY SESSION - PRIZE COMPETITION

The NFKK young researcher award

Chair: Professor *Lars Melholt Rasmussen* (Odense, DK)

NFKK Prize Competition

The Nordic Society for Clinical Chemistry rewards contemporary Nordic research work related to the field of clinical chemistry by the *NFKK Young Researcher Award* (previously known as *The Astrup Prize*)

Nordic scientists below 40 years of age who have not previously received the Astrup Prize are invited to submit an abstract. Abstracts are judged by a committee consisting of five senior scientists within the clinical chemistry field – one from each Nordic country.

Three abstracts are selected for oral presentation at the Nordic Congress and the prize committee will award 3 prizes at a value of respectively DKK 40,000, DKK 20,000 and DKK 10,000 for 1st, 2nd and 3rd prize.

The prizes will be awarded to the winners during the gala dinner on September 17th.

12:00-13:00 LUNCH

12:30-13:00 POSTERWALK I

13:00 -13:45 PLENARY LECTURE

Next steps for microbiome therapies: mechanism of action

Chairs: TBA

Professor *Curtis Huttenhower*, Harvard Chan Microbiome in Public Health Center, Harvard University, Boston, USA



Several microbiome-derived therapies have now received or are undergoing regulatory approval, including both live biotherapeutic products (LBPs) and bioactive small molecules of microbial origin. However, almost none have established mechanisms of action, be they chemical, immune-mediated, ecological, or otherwise. This process is impeded by the extent of microbial “dark matter” even in the well-studied human gut microbiome: some 50-75% of microbial proteins cannot be assigned even putative function from metagenomes alone, and this fraction is above 95% in other environments. We have developed new methods that provide potential pathway assignments for approximately 25% of human gut microbiome proteins, as well as guidelines for extending them to other hosts and environments. Examples include new chemotaxis and B-vitamin metabolism cassettes in *Hungatella hathewayi*, implicated in inflammatory bowel disease and colorectal cancer, and CRISPR system members in the “anti-inflammatory” *Faecalibacterium prausnitzii*. In addition to metabolic functions, many previously uncharacterized sequences are likely to be viral, and we find perturbations in both DNA and RNA viromes during inflammation (e.g. *E. coli* phage correlated with increased *E. coli* abundance) using novel profiling methods. Finally, many of these new functions can be linked to small molecule chemistry as well, e.g. putative bilirubin derivatives depleted in IBD. These approaches thus aid in identifying the molecular mechanisms underlying ecological, metabolic, and disease phenotypes and treatments.

13:55 - 14:15 COMPANY SESSION

Siemens Healthcare A/S

13:55 - 14:15 COMPANY SESSION

Sarstedt ApS

13:55 - 14:15 COMPANY SESSION

Vingmed A/S

14:30 - 16:00 SESSION 10

Fibrinogen and fibrinolysis in health and disease

Chair: Associate Professor *Julie Brogaard Larsen* (Aarhus DK)

14:30 - 15:00

14:30 - 16:00 SESSION 11

AI in Diagnostics: Where are we now and what lies ahead?

Chairs: Associate Professor *Anders Mønsted Abildgaard* (Aarhus DK) and Associate Professor *Stefan Stender* (Copenhagen DK)

14:30 - 15:00

14:30 - 16:00 SESSION 12

Mass spectrometry-based proteomics in clinical biochemistry

Chairs: Professor *Hans Christian Beck* (Odense DK) and associate professor *Martin Overgaard* (Odense DK)

14:30 - 14:55

Fibrinolysis: How to measure, and why?

Associate Professor *Julie Brogaard Larsen*

Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark

15:00 - 15:30

Fibrinogen in health and disease

Professor *Else Marie Bladbjerg*

Department of Clinical Biochemistry, University Hospital of Southern Denmark, Esbjerg, Denmark

15:30 - 15:50

Fibrinolysis in venous thromboembolic disease

PhD student *Anne Lind Malte*

Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark

16:15 - 17:45 SESSION 13

Outcome studies in laboratory medicine

Chair: Head of Medical Section *Erik Koldberg Amundsen* (Oslo, NO)

16:15 - 16:45

Introduction to outcomes studies in laboratory medicine with focus on pragmatic implementation studies, IFCC TF-OSLM.

Head of Medical Section *Erik Koldberg Amundsen*

Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway

16:45 - 17:05

Modelling for outcome studies and health economic outcomes

Senior Director Medical Affairs *Paul Jülicher*

Health Economics & Outcomes Research, Core Diagnostics, Abbott, Germany.

17:05 - 17:25

Cluster-based study designs. Interventions to improve appropriateness of test ordering in primary care

Biochemist *Serena Lillo*

Department of Biochemistry and Immunology, Lillebaelt Hospital, Vejle, Denmark

17:25 - 17:45

RCTs in laboratory medicine. The WESTCOR-POC study, use of POC Troponin in the Emergency Department

Professor *Kristin Moberg Aakre*

Haukeland University Hospital and Department of Clinical Science University of Bergen, Bergen, Norway.

TBA

Medical and Scientific Affairs Lead *Andreas Pihl*

Roche Diagnostics, Denmark

15:00 - 15:30

From Data to Diagnosis: Making AI Reliable in Laboratory Medicine

Medical Director *Andreas Bietenbeck*

Labor Poing, Munich, Germany

15:30 - 16:00

Bespoke Biology: How AI-Designed Proteins are Reimagining Diagnostics and Therapeutics

Postdoctoral researcher *Kasper Haldrup*

Digital Biotechnology Lab, Technical University of Denmark, Kongens Lyngby,

16:15 - 17:45 SESSION 14

Updates from Nordic screening and screening pilots (session by SKKY)

Chair: Chief physician *Anna Linko-Parvinen* (Turku, FI)

16:15 - 16:45

Lipoprotein (a) cascade screening in cardiovascular disease

Specialist Dr. *Karin Littman*

Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden

16:45 - 17:15

Current strategies in prostate cancer screening

Professor *Anssi Auvinen*

Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University, Finland

TBA

Proteomics—Illusion or Diagnostic Revolution?

Professor *Nicolai J. Wewer Albrechtsen*

Department of Clinical Biochemistry, Copenhagen University Hospital, Copenhagen, Denmark

14:55 - 15:20

Dried blood spots and other smart-samplers: Advancing Clinical LC-MS Protein Bioanalysis

Professor *Trine Grønhaug Halvorsen*

Section for Pharmaceutical Chemistry, Oslo University

15:20 - 15:45

Subtyping of amyloidosis and diagnosis of other rare protein deposition diseases by mass spectrometry-based proteomics

Professor *Hans Christian Beck*

Department of Clinical Biochemistry, Odense University Hospital, Odense, DK

15:45 - 16:00

Selected abstract

16:15 - 17:45 SESSION 15

The microbiome and human health

Chairs: Clinical Bioinformatician *Louise Bruun Thingholm* (Aarhus DK) and Professor *Christian Lodberg Hvas* (Aarhus DK)

16:15 - 16:45

Gut virome and human health

Professor *Dennis Sandris Nielsen*

Department of Food Science, University of Copenhagen; Copenhagen, Denmark

16:45 - 17:15

Fecal microbiome transplantation (FMT) – optimising the clinical effect

Professor *Christian Lodberg Hvas*

Department of Gastroenterology, Aarhus University Hospital, Aarhus, Denmark

17:15 - 17:45

Pharmaco-microbiomics – drug metabolism by the microbiome

Adjunct Senior Lecturer *Piotr Nowak*

Department of Infectious Diseases, Karolinska University Hospital, Huddinge, Sweden